Treatment Options for Motor and Non-Motor Symptoms of Parkinson's Disease
- PMID: 33924103
- PMCID: PMC8074325
- DOI: 10.3390/biom11040612
Treatment Options for Motor and Non-Motor Symptoms of Parkinson's Disease
Abstract
Parkinson's disease (PD) usually presents in older adults and typically has both motor and non-motor dysfunctions. PD is a progressive neurodegenerative disorder resulting from dopaminergic neuronal cell loss in the mid-brain substantia nigra pars compacta region. Outlined here is an integrative medicine and health strategy that highlights five treatment options for people with Parkinson's (PwP): rehabilitate, therapy, restorative, maintenance, and surgery. Rehabilitating begins following the diagnosis and throughout any additional treatment processes, especially vis-à-vis consulting with physical, occupational, and/or speech pathology therapist(s). Therapy uses daily administration of either the dopamine precursor levodopa (with carbidopa) or a dopamine agonist, compounds that preserve residual dopamine, and other specific motor/non-motor-related compounds. Restorative uses strenuous aerobic exercise programs that can be neuroprotective. Maintenance uses complementary and alternative medicine substances that potentially support and protect the brain microenvironment. Finally, surgery, including deep brain stimulation, is pursued when PwP fail to respond positively to other treatment options. There is currently no cure for PD. In conclusion, the best strategy for treating PD is to hope to slow disorder progression and strive to achieve stability with neuroprotection. The ultimate goal of any management program is to improve the quality-of-life for a person with Parkinson's disease.
Keywords: Parkinson’s disease; anti-inflammatory; antioxidants; carbidopa/levodopa; integrative medicine; motor and non-motor symptoms; neurodegenerative disorder; older adults; substantia nigra.
Conflict of interest statement
The author declares no conflict of interest.
Figures



Similar articles
-
Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.Brain. 2009 Feb;132(Pt 2):309-18. doi: 10.1093/brain/awn322. Epub 2008 Dec 2. Brain. 2009. PMID: 19050033
-
International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease.Mov Disord. 2018 Aug;33(8):1248-1266. doi: 10.1002/mds.27372. Epub 2018 Mar 23. Mov Disord. 2018. PMID: 29570866 Review.
-
Beta-band oscillations in the supplementary motor cortex are modulated by levodopa and associated with functional activity in the basal ganglia.Neuroimage Clin. 2018 May 18;19:559-571. doi: 10.1016/j.nicl.2018.05.021. eCollection 2018. Neuroimage Clin. 2018. PMID: 29984164 Free PMC article.
-
Neural substrates and potential treatments for levodopa-induced dyskinesias in Parkinson's disease.Rev Neurosci. 2016 Oct 1;27(7):729-738. doi: 10.1515/revneuro-2016-0009. Rev Neurosci. 2016. PMID: 27362959 Review.
-
Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson's disease: a double-blind, randomised controlled trial.Lancet Neurol. 2019 Nov;18(11):998-1008. doi: 10.1016/S1474-4422(19)30285-6. Epub 2019 Sep 11. Lancet Neurol. 2019. PMID: 31521532 Clinical Trial.
Cited by
-
Exercise, Neuroprotective Exerkines, and Parkinson's Disease: A Narrative Review.Biomolecules. 2024 Sep 30;14(10):1241. doi: 10.3390/biom14101241. Biomolecules. 2024. PMID: 39456173 Free PMC article. Review.
-
Action Observation and Motor Imagery as a Treatment in Patients with Parkinson's Disease.J Parkinsons Dis. 2024;14(s1):S53-S64. doi: 10.3233/JPD-230219. J Parkinsons Dis. 2024. PMID: 38250785 Free PMC article. Review.
-
Alternative Therapies for Non-Motor Symptoms in Parkinson's Disease: A Mini Review.Neuropsychiatr Dis Treat. 2024 Dec 21;20:2585-2591. doi: 10.2147/NDT.S495092. eCollection 2024. Neuropsychiatr Dis Treat. 2024. PMID: 39723118 Free PMC article. Review.
-
Analytical method for simultaneous quantification of levodopa and carbidopa in the injectable oleogel formulation by HPLC.BMC Chem. 2025 Feb 17;19(1):43. doi: 10.1186/s13065-025-01410-8. BMC Chem. 2025. PMID: 39962556 Free PMC article.
-
Salivary Biomarkers for Parkinson's Disease: A Systematic Review with Meta-Analysis.Cells. 2024 Feb 14;13(4):340. doi: 10.3390/cells13040340. Cells. 2024. PMID: 38391952 Free PMC article.
References
-
- Werner P., Seppi K., Tanner C.M., Halliday G.M., Brundin P., Volkmann J., Schrag A.E., Lang A.E. Parkinson disease. Nat. Rev. Dis. Primers. 2017;3:17013. - PubMed
-
- Ahlskog J.E. The New Parkinson’s Disease Treatment Book: Partnering with Your Doctor to Get the Most from Your Medications. Oxford University Press; Oxford, UK: 2015.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous